etoposide has been researched along with trimetrexate in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (8.33) | 18.7374 |
| 1990's | 6 (50.00) | 18.2507 |
| 2000's | 3 (25.00) | 29.6817 |
| 2010's | 1 (8.33) | 24.3611 |
| 2020's | 1 (8.33) | 2.80 |
| Authors | Studies |
|---|---|
| Hansch, C; Khwaja, TA; Selassie, CD | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| González-Díaz, H; Orallo, F; Quezada, E; Santana, L; Uriarte, E; Viña, D; Yáñez, M | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Bansal, R; Malhotra, A | 1 |
| Miyachi, H; Ohnuma, T; Sekiguchi, S; Takemura, Y | 1 |
| Fry, DW | 1 |
| Maroun, JA; Natale, RB; Robert, F | 1 |
| Holden, SA; Northey, D; Robinson, MF; Rosowsky, A; Teicher, BA | 1 |
| Benaim, E; Blakley, RL; Galipeau, J; Sorrentino, BP; Spencer, HT | 1 |
| Blum, RH; Bonomi, P; Boucher, H; Chang, AY; Karp, DD; Kim, K; Stewart, JA | 1 |
2 review(s) available for etoposide and trimetrexate
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Therapeutic progression of quinazolines as targeted chemotherapeutic agents.
Topics: Animals; Antineoplastic Agents; Cell Proliferation; Enzyme Inhibitors; Humans; Molecular Structure; Neoplasms; Quinazolines | 2021 |
1 trial(s) available for etoposide and trimetrexate
| Article | Year |
|---|---|
A randomized phase II trial of echinomycin, trimetrexate, and cisplatin plus etoposide in patients with metastatic nonsmall cell lung carcinoma: an Eastern Cooperative Oncology Group Study (E1587).
Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Drug Administration Schedule; Echinomycin; Etoposide; Female; Humans; Infusions, Intravenous; Injections, Intravenous; Intercalating Agents; Lung Neoplasms; Male; Middle Aged; Prognosis; Quality of Life; Remission Induction; Survival Rate; Trimetrexate | 1998 |
9 other study(ies) available for etoposide and trimetrexate
| Article | Year |
|---|---|
Structure-activity relationships of antineoplastic agents in multidrug resistance.
Topics: Animals; Antineoplastic Agents; Cell Line; Cell Survival; Cricetinae; Dactinomycin; Drug Resistance; Leukemia L1210; Mice; Regression Analysis; Structure-Activity Relationship; Tumor Cells, Cultured | 1990 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
Topics: Computational Biology; Drug Design; Humans; Isoenzymes; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quantitative Structure-Activity Relationship | 2008 |
A human leukemia cell line made resistant to two folate analogues, trimetrexate and N10-propargyl-5,8-dideazafolic acid (CB3717).
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Division; Cell Line; Cisplatin; Cross Reactions; Dactinomycin; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance; Etoposide; Fluorouracil; Folic Acid; Humans; Leucovorin; Membrane Glycoproteins; Methotrexate; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Quinazolines; RNA, Messenger; Thymidylate Synthase; Trimetrexate; Vincristine | 1991 |
Cytotoxic synergism between trimetrexate and etoposide. Evidence that trimetrexate potentiates etoposide-induced protein-associated DNA strand breaks in L1210 leukemia cells through alterations in intracellular ATP concentrations.
Topics: Adenosine Triphosphate; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Survival; DNA Damage; DNA, Neoplasm; Etoposide; Leukemia L1210; Mice; Quinazolines; Trimetrexate; Tumor Cells, Cultured | 1990 |
Trimetrexate combined with cisplatin or etoposide in the treatment of non-small cell lung cancer: a pilot study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carcinoma, Non-Small-Cell Lung; Cisplatin; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Trimetrexate | 1988 |
Antifolates can potentiate topoisomerase II inhibitors in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Division; Cell Line; Cell Survival; DNA Damage; DNA, Neoplasm; Drug Synergism; Etoposide; Folic Acid Antagonists; Head and Neck Neoplasms; Humans; Male; Methotrexate; Mice; Mice, Inbred C3H; Novobiocin; Ornithine; Pterins; Topoisomerase II Inhibitors; Trimetrexate; Tumor Cells, Cultured | 1995 |
A bicistronic retroviral vector for protecting hematopoietic cells against antifolates and P-glycoprotein effluxed drugs.
Topics: Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cells, Cultured; Cloning, Molecular; Drug Resistance, Multiple; Etoposide; Folic Acid Antagonists; Gene Expression; Genetic Vectors; Hematopoietic Stem Cells; Humans; Methotrexate; Paclitaxel; Proviruses; Retroviridae; Tetrahydrofolate Dehydrogenase; Transformation, Genetic; Trimetrexate; Tumor Cells, Cultured; Vinblastine | 1997 |